Thrombocytopenia, neutropenia, and anemia are the most commonly reported hematologic toxicities reported during monotherapy with the mTOR inhibitors everolimus, temsirolimus, and ridaforolimus [38-44]. The gene discussed is MTOR; the disease is Decreased total neutrophil count.